Glenkast-LC Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, mitigating bronchoconstriction, inflammation, and mucus production associated with allergic responses and asthma. The synergistic action of these agents provides comprehensive relief from both immediate and delayed allergic symptoms. Glenkast-LC is particularly beneficial in patients requiring control of nasal and respiratory allergies alongside leukotriene-mediated inflammation. The tablet is administered orally, typically once daily in the evening, with or without food, as prescribed by a healthcare professional. Common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances, though the combination is generally well tolerated. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with hypersensitivity to either component. Glenkast-LC should be used under medical supervision to ensure optimal therapeutic outcomes and to monitor for potential drug interactions or side effects.